At its November 2025 meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended a new Restricted Benefit listing on the Pharmaceutical Benefits Scheme (PBS) for lamotrigine to treat bipolar disorder.
A Public Summary Document for this item is now available on the Lamotrigine for bipolar disorder webpage.
If you have any questions relating to this item, please email PBSpostmarket@health.gov.au